← Back to Clinical Trials
RecruitingNCT06675903

Continuous Glucose Monitoring (CGM) After Kidney Transplantation

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

ConditionHyperglycaemia
SponsorBo Feldt-Rasmussen
Study TypeOBSERVATIONAL
PhaseN/A
Enrollment54
SexALL
Min Age18 Years
Max AgeN/A
Start Date2024-11-12
Completion2026-01-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This study examines glucose levels measured by continuous glucose monitoring (CGM) in the immediate period following kidney transplantation among recipients with diabetes, without diabetes, and with pre-diabetes. The primary objective is to analyse differences in mean sensor glucose between these three groups. CGMs are applied to participants within 72 hours after kidney transplantation, with a total of 54 participants divided equally across the three groups (18 in each). Secondary objectives include assessing additional glucose profile indices, adherence to relevant guidelines, changes in HbA1c, the impact of immunosuppression and steroid dosage, and beta cell function.

Eligibility Criteria

Inclusion Criteria: * Written informed consent obtained before CGM application * Male or female; age: ≥18 years * Kidney transplantation Exclusion Criteria: * Unable to cooperate to CGM the first ten days after surgery * Allergic to plasters in CGM units * Combined kidney and liver or pancreatic transplantation * Graft loss/rejection within first 48 hours after transplantation

Related Trials